Lyra Therapeutics, Inc.
LYRA
$0.73
-$0.01-1.22%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.95M | -5.98M | -7.44M | -8.55M | -10.98M |
| Total Depreciation and Amortization | 100.00K | 104.00K | 127.00K | 128.00K | 151.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | 0.00 |
| Total Other Non-Cash Items | 562.00K | 34.00K | 906.00K | 825.00K | 1.67M |
| Change in Net Operating Assets | 223.00K | -1.52M | -186.00K | -1.25M | -2.20M |
| Cash from Operations | -6.07M | -7.36M | -6.59M | -8.84M | -11.35M |
| Capital Expenditure | -96.00K | 0.00 | -20.00K | -- | 58.00K |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 18.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 28.07M |
| Cash from Investing | -96.00K | 0.00 | -2.00K | -- | 28.13M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 0.00 | 5.00M | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -1.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -368.00K | -358.00K | -- | 0.00 |
| Cash from Financing | 0.00 | -368.00K | 4.64M | -- | -1.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.16M | -7.73M | -1.95M | -8.84M | 16.78M |